Claims for Patent: 8,278,353

Summary for Patent: 8,278,353

Title:	Enhanced bimatoprost ophthalmic solution
Abstract:	A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/370,574
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,278,353
Patent Claims:	1. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 2. The composition of claim 1 wherein the first composition has a pH of about 7.3. 3. The composition of claim 1 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 4. The composition of claim 1 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 5. The composition of claim 1 wherein the first composition is effective in treating glaucoma. 6. The composition of claim 1 wherein the first composition is effective in treating ocular hypertension. 7. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 8. The composition of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. 9. The composition of claim 7 wherein the first composition has a pH of about 7.3. 10. The composition of claim 7 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 11. The composition of claim 7 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 12. The composition of claim 7 wherein the first composition is applied topically. 13. The composition of claim 7 wherein the first composition is effective in treating glaucoma. 14. The composition of claim 7 wherein the first composition is effective in treating ocular hypertension. 15. A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein first the composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 16. The composition of claim 15 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. 17. The composition of claim 15 wherein the first composition has a pH of about 7.3. 18. The composition of claim 15 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 19. The composition of claim 15 wherein the first composition is a solution. 20. The composition of claim 15 wherein the first composition is effective in treating glaucoma. 21. The composition of claim 20 wherein the glaucoma is open-angle glaucoma. 22. The composition of claim 15 wherein the first composition is effective in treating ocular hypertension. 23. A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, wherein the first composition comprises about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the benzalkonium chloride concentration of the first composition increases the permeability of bimatoprost across corneal epithelial cell layers as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 24. The composition of claim 23 wherein the first composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the second composition. 25. The composition of claim 23 wherein the first composition results in less hyperemia as compared to the once daily administration of the second composition. 26. The composition of claim 23 wherein the first composition is effective in treating glaucoma. 27. The composition of claim 23 wherein the composition is effective in treating ocular hypertension. 28. The composition of claim 23 wherein the first composition has a pH of about 7.3. 29. The composition of claim 23 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 30. The composition of claim 23 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.